Key Points
-
DNA methyltransferase 3A (DNMT3A) belongs to a family of highly conserved DNA methyltransferases that catalyse 5-methylcytosine methylation. Regulatory domains of DNMT3A allow interactions with histone methyltransferases and histones to influence gene expression.
-
DNMT3A is important in embryonic and haematopoietic stem cell (HSC) differentiation, and interacts with DNMT3B to regulate the function of stem cells. Loss of murine Dnmt3a causes unprecedented HSC expansion, clonal dominance, aberrant DNA methylation, an unrepressed stem cell programme and, eventually, haematological malignancies.
-
DNMT3A mutations occur in human HSCs, in which they can act as a pre-leukaemic lesion. Mutant HSC progeny are found in all differentiated lineages in some patients with acute myeloid leukaemia (AML), and mutant HSCs persist during disease remission.
-
DNMT3A mutations occur in diverse haematological malignancies with unique mutational profiles. The R882 hotspot mutation occurs most frequently in AML and has been shown to act as a dominant-negative inhibitor of wild-type DNMT3A enzymatic activity.
-
DNMT3A mutations non-randomly co-occur with a number of other mutations but can also be essentially mutually exclusive of others. This pattern suggests important biological relationships among these genes.
-
The prognostic impact of DNMT3A mutations across various haematological malignancies is inconclusive. A number of studies have found that mutations of DNMT3A confer a poor prognosis, but others have found that DNMT3A status is prognostically neutral.
-
Haematopoiesis becomes clonal in a significant portion of ageing individuals and is associated with increased incidence of haematological malignancy and all-cause mortality; mutations in DNMT3A are highly associated with this phenomenon.
-
Given the strong association between DNMT3A mutations and many types of haematological malignancy and the relatively poor understanding of its mechanistic function, DNMT3A represents an important new target for research and novel therapeutic approaches.
Abstract
DNA methylation patterns are disrupted in various malignancies, suggesting a role in the development of cancer, but genetic aberrations directly linking the DNA methylation machinery to malignancies were rarely observed, so this association remained largely correlative. Recently, however, mutations in the gene encoding DNA methyltransferase 3A (DNMT3A) were reported in patients with acute myeloid leukaemia (AML), and subsequently in patients with various other haematological malignancies, pointing to DNMT3A as a critically important new tumour suppressor. Here, we review the clinical findings related to DNMT3A, tie these data to insights from basic science studies conducted over the past 20 years and present a roadmap for future research that should advance the agenda for new therapeutic strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Peters, S. L. et al. Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. Mol. Cell. Biol. 33, 4321–4333 (2013).
Laird, P. W. et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81, 197–205 (1995).
Broske, A. M. et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nature Genet. 41, 1207–1215 (2009).
Kim, M. S., Kim, Y. R., Yoo, N. J. & Lee, S. H. Mutational analysis of DNMT3A gene in acute leukemias and common solid cancers. Apmis 121, 85–94 (2013).
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011).
Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21 (2002).
Holliday, R. & Grigg, G. W. DNA methylation and mutation. Mutat. Res. 285, 61–67 (1993).
You, J. S. & Jones, P. A. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22, 9–20 (2012).
Galm, O., Herman, J. G. & Baylin, S. B. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 20, 1–13 (2006).
Weisenberger, D. J. et al. Identification and characterization of alternatively spliced variants of DNA methyltransferase 3a in mammalian cells. Gene 298, 91–99 (2002).
Schoofs, T. & Müller-Tidow, C. DNA methylation as a pathogenic event and as a therapeutic target in AML. Cancer Treat. Rev. 37 (Suppl. 1), 1–6 (2011).
Hansen, K. D. et al. Increased methylation variation in epigenetic domains across cancer types. Nature Genet. 43, 768–775 (2011).
Okano, M., Xie, S. & Li, E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nature Genet. 19, 219–220 (1998).
Wienholz, B. L. et al. DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo. PLoS Genet. 6, e1001106 (2010).
Kaneda, M. et al. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature 429, 900–903 (2004).
Cedar, H. & Bergman, Y. Epigenetics of haematopoietic cell development. Nature Rev. Immunol. 11, 478–488 (2011).
Subramaniam, D., Thombre, R., Dhar, A. & Anant, S. DNA methyltransferases: a novel target for prevention and therapy. Front. Oncol. 4, 80 (2014).
Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).
Pastor, W. A. et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473, 394–397 (2011).
Inoue, A. & Zhang, Y. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science 334, 194 (2011).
Robertson, K. D. et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 27, 2291–2298 (1999).
Xie, S. et al. Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene 236, 87–95 (1999).
Chen, T., Ueda, Y., Xie, S. & Li, E. A novel Dnmt3a isoform produced from an alternative promoter localizes to euchromatin and its expression correlates with active de novo methylation. J. Biol. Chem. 277, 38746–38754 (2002).
Tadokoro, Y., Ema, H., Okano, M., Li, E. & Nakauchi, H. De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J. Exp. Med. 204, 715–722 (2007).
Yanagisawa, Y., Ito, E., Yuasa, Y. & Maruyama, K. The human DNA methyltransferases DNMT3A and DNMT3B have two types of promoters with different CpG contents. Biochim. Biophys. Acta 1577, 457–465 (2002).
Suetake, I. et al. Characterization of DNA-binding activity in the N-terminal domain of the DNA methyltransferase Dnmt3a. Biochem. J. 437, 141–148 (2011).
Dhayalan, A. et al. The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. J. Biol. Chem. 285, 26114–26120 (2010).
Fuks, F., Burgers, W. A., Godin, N., Kasai, M. & Kouzarides, T. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 20, 2536–2544 (2001).
Otani, J. et al. Structural basis for recognition of H3K4 methylation status by the DNA methyltransferase 3A ATRX-DNMT3-DNMT3L domain. EMBO Rep. 10, 1235–1241 (2009).
Zhang, Y. et al. Chromatin methylation activity of Dnmt3a and Dnmt3a/3L is guided by interaction of the ADD domain with the histone H3 tail. Nucleic Acids Res. 38, 4246–4253 (2010).
Guo, X. et al. Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature http://dx.doi.org/10.1038/nature13899 (2014). References 30 and 32 demonstrate that the auto-inhibitory function of the ADD domain of DNMT3A provides the link between H3K4 methylation and DNMT3A.
Xu, F. et al. Molecular and enzymatic profiles of mammalian DNA methyltransferases: structures and targets for drugs. Curr. Med. Chem. 17, 4052–4071 (2010).
Jia, D., Jurkowska, R. Z., Zhang, X., Jeltsch, A. & Cheng, X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 449, 248–251 (2007).
Holz-Schietinger, C. & Reich, N. O. The inherent processivity of the human de novo methyltransferase 3A (DNMT3A) is enhanced by DNMT3L. J. Biol. Chem. 285, 29091–29100 (2010).
Chen, T., Ueda, Y., Dodge, J. E., Wang, Z. & Li, E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol. Cell. Biol. 23, 5594–5605 (2003). This article deeply explores the phenotype in ESCs of ablation of Dnmt3a and Dnmt3b , establishing the paradigm of extended self-renewal and DNA methylation loss, foreshadowing the somatic stem cell phenotype.
Ostler, K. R. et al. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene 26, 5553–5563 (2007).
Gordon, C. A., Hartono, S. R. & Chedin, F. Inactive DNMT3B splice variants modulate de novo DNA methylation. PLoS ONE 8, e69486 (2013).
Bachman, K. E., Rountree, M. R. & Baylin, S. B. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem. 276, 32282–32287 (2001).
Chen, T., Tsujimoto, N. & Li, E. The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at pericentric heterochromatin. Mol. Cell. Biol. 24, 9048–9058 (2004).
Hattori, N. et al. Preference of DNA methyltransferases for CpG islands in mouse embryonic stem cells. Genome Res. 14, 1733–1740 (2004).
Choi, S. H. et al. Identification of preferential target sites for human DNA methyltransferases. Nucleic Acids Res. 39, 104–118 (2011).
Robertson, A. K., Geiman, T. M., Sankpal, U. T., Hager, G. L. & Robertson, K. D. Effects of chromatin structure on the enzymatic and DNA binding functions of DNA methyltransferases DNMT1 and Dnmt3a in vitro. Biochem. Biophys. Res. Commun. 322, 110–118 (2004).
Takeshima, H. et al. Distinct DNA methylation activity of Dnmt3a and Dnmt3b towards naked and nucleosomal DNA. J. Biochem. 139, 503–515 (2006).
Yang, Y. et al. CRL4B promotes tumorigenesis by coordinating with SUV39H1/HP1/DNMT3A in DNA methylation-based epigenetic silencing. Oncogene 34, 104–118 (2013).
Weissmann, F. et al. DNA hypermethylation in Drosophila melanogaster causes irregular chromosome condensation and dysregulation of epigenetic histone modifications. Mol. Cell. Biol. 23, 2577–2586 (2003).
Fuks, F., Hurd, P. J., Deplus, R. & Kouzarides, T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 31, 2305–2312 (2003).
Muramatsu, D., Singh, P. B., Kimura, H., Tachibana, M. & Shinkai, Y. Pericentric heterochromatin generated by HP1 protein interaction-defective histone methyltransferase Suv39h1. J. Biol. Chem. 288, 25285–25296 (2013).
Karimi, M. M. et al. DNA methylation and SETDB1/H3K9me3 regulate predominantly distinct sets of genes, retroelements, and chimeric transcripts in mESCs. Cell Stem Cell 8, 676–687 (2011).
Epsztejn-Litman, S. et al. De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes. Nature Struct. Mol. Biol. 15, 1176–1183 (2008).
Chang, Y. et al. MPP8 mediates the interactions between DNA methyltransferase Dnmt3a and H3K9 methyltransferase GLP/G9a. Nature Commun. 2, 533 (2011).
Rush, M. et al. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. Epigenetics 4, 404–414 (2009).
Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871–874 (2006).
Jeong, M. et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nature Genet. 46, 17–23 (2014). This paper defines 'DNA methylation canyons', which are large, under-methylated regions of the genome that are particularly affected by the loss of DNMT3A. It is also suggested that TET proteins and histone marks interplay at canyons.
Xie, W. et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell 153, 1134–1148 (2013).
Wu, H. et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 329, 444–448 (2010).
Meissner, A. et al. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 33, 5868–5877 (2005).
Lin, I. G., Han, L., Taghva, A., O'Brien, L. E. & Hsieh, C. L. Murine de novo methyltransferase Dnmt3a demonstrates strand asymmetry and site preference in the methylation of DNA in vitro. Mol. Cell. Biol. 22, 704–723 (2002).
Handa, V. & Jeltsch, A. Profound flanking sequence preference of Dnmt3a and Dnmt3b mammalian DNA methyltransferases shape the human epigenome. J. Mol. Biol. 348, 1103–1112 (2005).
Gowher, H. et al. Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase. J. Mol. Biol. 357, 928–941 (2006). This paper describes a mutational analysis that reveals the key role of specific residues in the catalytic domain of DNMT3A.
Suetake, I., Miyazaki, J., Murakami, C., Takeshima, H. & Tajima, S. Distinct enzymatic properties of recombinant mouse DNA methyltransferases Dnmt3a and Dnmt3b. J. Biochem. 133, 737–744 (2003).
Gowher, H. & Jeltsch, A. Enzymatic properties of recombinant Dnmt3a DNA methyltransferase from mouse: the enzyme modifies DNA in a non-processive manner and also methylates non-CpG [correction of non-CpA] sites. J. Mol. Biol. 309, 1201–1208 (2001).
Ramsahoye, B. H. et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc. Natl Acad. Sci. USA 97, 5237–5242 (2000).
Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766–770 (2008).
Lister, R. et al. Global epigenomic reconfiguration during mammalian brain development. Science 341, 1237905 (2013).
Guo, J. U. et al. Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. Nature Neurosci. 17, 215–222 (2014).
Ziller, M. J. et al. Genomic distribution and inter-sample variation of non-CpG methylation across human cell types. PLoS Genet. 7, e1002389 (2011).
Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247–257 (1999).
Schmidt, C. S. et al. Global DNA hypomethylation prevents consolidation of differentiation programs and allows reversion to the embryonic stem cell state. PLoS ONE 7, e52629 (2012).
Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature Genet. 44, 23–31 (2012). This article shows that ablation of Dnmt3a in HSCs leads to stem cell expansion and inhibited differentiation, providing the conceptual framework for understanding the role of DNMT3A mutations in human haematological malignancies.
Challen, G. A. et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 15, 350–364 (2014). This article shows the roles of DNMT3B and DNMT3A in HSC differentiation, implicating the β-catenin pathway, upregulation of self-renewal genes and attendant epigenetic changes in the molecular and cellular phenotype.
Hao, J., Li, T. G., Qi, X., Zhao, D. F. & Zhao, G. Q. WNT/β-catenin pathway up-regulates Stat3 and converges on LIF to prevent differentiation of mouse embryonic stem cells. Dev. Biol. 290, 81–91 (2006).
Wu, Z. et al. Dnmt3a regulates both proliferation and differentiation of mouse neural stem cells. J. Neurosci. Res. 90, 1883–1891 (2012).
Tatton-Brown, K. et al. Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability. Nature Genet. 46, 385–388 (2014).
Yamashita, Y. et al. Array-based genomic resequencing of human leukemia. Oncogene 29, 3723–3731 (2010).
Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010). This seminal paper reports the frequency and clinical significance of DNMT3A mutations in a large cohort of patients with acute myeloid leukaemia.
Yan, X. J. et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nature Genet. 43, 309–315 (2011).
The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013). This work is a comprehensive genetic and epigenetic analysis of patients with AML that provides a valuable database of patients with DNMT3A and other commonly occurring mutations.
Huether, R. et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nature Commun. 5, 3630 (2014).
Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506–510 (2012).
Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264–278 (2012).
Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328–333 (2014). This study identifies DNMT3Amut HSCs as the pre-leukaemic founding clones in AML.
Corces-Zimmerman, M. R., Hong, W. J., Weissman, I. L., Medeiros, B. C. & Majeti, R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc. Natl Acad. Sci. USA 111, 2548–2553 (2014). This study demonstrates the existence of pre-leukaemic HSCs in AML and at remission, and the predominance of mutations in epigenetic modifiers, including DNMT3A.
Xie, M. et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Med. 20, 1472–1478 (2014).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014). References 84, 85 and 86 demonstrate the striking age-related increase of clonal haematopoiesis and highlight DNMT3A mutations as being highly correlated with this state.
Mayle, A. et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 125, 629–638 (2014).
Celik, H. et al. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 125, 619–628 (2014). References 87 and 88 show that ablation (knockout) of Dnmt3a in mouse stem cells can recapitulate the range of haematological malignancies seen in patients, despite the distinct genetic lesions observed in such malignancies.
Patel, J. P. et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366, 1079–1089 (2012). This study reports the frequency and prognostic relevance of DNMT3A mutations and other recurrent mutations in a large, uniformly treated cohort of adults with AML.
Shen, Y. et al. Gene mutation patterns and their prognostic impact in a cohort of 1,185 patients with acute myeloid leukemia. Blood 118, 5593–5603 (2011).
Ribeiro, A. F. T. et al. Mutant DNMT3A: a new marker of poor prognosis in acute myeloid leukemia. Blood 119, 5824–5831 (2012).
Gaidzik, V. I. et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 121, 4769–4777 (2013).
Hou, H. A. et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 28, 50–58 (2014).
Hou, Y. et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148, 873–885 (2012).
Bejar, R. et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30, 3376–3382 (2012).
Roller, A. et al. Landmark analysis of DNMT3A mutations in hematological malignancies. Leukemia 27, 1573–1578 (2013).
Walter, M. J. et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25, 1153–1158 (2011).
Stegelmann, F. et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 25, 1217–1219 (2011).
Abdel-Wahab, O. et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25, 1219–1220 (2011).
Jankowska, A. M. et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118, 3932–3941 (2011).
Odejide, O. et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123, 1293–1296 (2014).
Palomero, T. et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature Genet. 46, 166–170 (2014).
Sakata-Yanagimoto, M. et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nature Genet. 46, 171–175 (2014). References 101–103 demonstrate the high frequency of DNMT3A mutations and their striking association with IDH and TET2 mutations in peripheral T cell lymphomas.
Grossmann, V. et al. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer 52, 410–422 (2013).
Holz-Schietinger, C., Matje, D. M. & Reich, N. O. Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation. J. Biol. Chem. 287, 30941–30951 (2012).
Holz-Schietinger, C., Matje, D. M., Harrison, M. F. & Reich, N. O. Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation. J. Biol. Chem. 286, 41479–41488 (2011). References 105 and 106 show the crucial role of DNMT3A oligomerization in maintaining high DNA methylation activity in addition to the mechanistic effect of specific AML-associated mutations.
Kim, S. J. et al. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 122, 4086–4089 (2013).
Russler-Germain, D. A. et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25, 442–454 (2014). References 107 and 108 provide insights into the common DNMT3A R882 mutation, showing that it can act as a dominant-negative mutationin mouse ESCs and human AML cells.
Qu, Y. et al. Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes. Epigenetics 9, 1108–1119 (2014).
Raddatz, G., Gao, Q., Bender, S., Jaenisch, R. & Lyko, F. Dnmt3a protects active chromosome domains against cancer-associated hypomethylation. PLoS Genet. 8, e1003146 (2012).
Ziller, M. J. et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 500, 477–481 (2013).
Stadler, M. B. et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 480, 490–495 (2011).
Dixon, J. R. et al. Topological domains in mammalian genomes identified by analysis of chromatin interactions. Nature 485, 376–380 (2012).
Ho, P. A. et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr. Blood Cancer 57, 204–209 (2011).
Hollink, I. H. I. M. et al. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. 26, 371–373 (2011).
Liang, D. C. et al. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A. Blood 121, 2988–2995 (2013).
Shiba, N. et al. DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia. Br. J. Haematol. 156, 413–414 (2012).
Thol, F. et al. DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica 96, 1238–1240 (2011).
Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157–163 (2012).
Figueroa, M. E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13–27 (2010).
Haferlach, T. et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 28, 241–247 (2014).
Damm, F. et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 119, 3211–3218 (2012).
Marcucci, G. et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J. Clin. Oncol. 30, 742–750 (2012).
Renneville, A. et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia 26, 1247–1254 (2012).
Hajkova, H. et al. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation. Leuk. Res. 36, 1128–1133 (2012).
Fried, I. et al. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia. Haematologica 97, 246–250 (2012).
Zebisch, A., Hoefler, G., Quehenberger, F., Wolfler, A. & Sill, H. Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability? Leukemia 27, 1777–1778 (2013).
Lu, C. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).
Thol, F. et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 119, 3578–3584 (2012).
Thol, F. et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J. Clin. Oncol. 29, 2889–2896 (2011).
Thol, F. et al. Rare occurence of DNMT3A mutations in myelodysplastic syndromes. Haematologica 96, 1870–1873 (2011).
Lin, C. C. et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am. J. Hematol. 89, 137–144 (2014).
Fried, I. et al. Mutations in DNMT3A and loss of RKIP are independent events in acute monocytic leukemia. Haematologica 97, 1936–1937 (2012).
Kar, S. A. et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica 98, 107–113 (2012).
Quintas-Cardama, A. et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 122, 893–901 (2013).
Van Vlierberghe, P. et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood 122, 74–82 (2013).
Neumann, M. et al. Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 121, 4749–4752 (2013).
LaRochelle, O. et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget 2, 850–861 (2011).
Herman, J. G. et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 57, 837–841 (1997).
Paul, T. A., Bies, J., Small, D. & Wolff, L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood 115, 3098–3108 (2010).
Toyota, M. et al. Methylation profiling in acute myeloid leukemia. Blood 97, 2823–2829 (2001).
Traina, F. et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 28, 78–87 (2014).
Klco, J. M. et al. Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 121, 1633–1643 (2013).
Ostronoff, F. et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia 27, 238–241 (2013).
Ross, D. M. et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24, 1719–1724 (2010).
Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genet. 44, 1179–1181 (2012).
Couronne, L., Bastard, C. & Bernard, O. A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366, 95–96 (2012).
Brown, S. J., Stoilov, P. & Xing, Y. Chromatin and epigenetic regulation of pre-mRNA processing. Hum. Mol. Genet. 21, R90–R96 (2012).
Luco, R. F., Allo, M., Schor, I. E., Kornblihtt, A. R. & Misteli, T. Epigenetics in alternative pre-mRNA splicing. Cell 144, 16–26 (2011).
Zemach, A., McDaniel, I. E., Silva, P. & Zilberman, D. Genome-wide evolutionary analysis of eukaryotic DNA methylation. Science 328, 916–919 (2010).
Kolasinska-Zwierz, P. et al. Differential chromatin marking of introns and expressed exons by H3K36me3. Nature Genet. 41, 376–381 (2009).
Laurent, L. et al. Dynamic changes in the human methylome during differentiation. Genome Res. 20, 320–331 (2010).
Regulski, M. et al. The maize methylome influences mRNA splice sites and reveals widespread paramutation-like switches guided by small RNA. Genome Res. 23, 1651–1662 (2013).
Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478, 64–69 (2011).
Jurkowska, R. Z., Jurkowski, T. P. & Jeltsch, A. Structure and function of mammalian DNA methyltransferases. Chembiochem 12, 206–222 (2011).
Purdy, M. M., Holz-Schietinger, C. & Reich, N. O. Identification of a second DNA binding site in human DNA methyltransferase 3A by substrate inhibition and domain deletion. Arch. Biochem. Biophys. 498, 13–22 (2010).
Kotini, A. G., Mpakali, A. & Agalioti, T. Dnmt3a1 upregulates transcription of distinct genes and targets chromosomal gene clusters for epigenetic silencing in mouse embryonic stem cells. Mol. Cell. Biol. 31, 1577–1592 (2011).
Ge, Y. Z. et al. Chromatin targeting of de novo DNA methyltransferases by the PWWP domain. J. Biol. Chem. 279, 25447–25454 (2004).
Li, B. Z. et al. Histone tails regulate DNA methylation by allosterically activating de novo methyltransferase. Cell Res. 21, 1172–1181 (2011).
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
Traina, F. et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS ONE 7, e43090 (2012).
Lin, J. et al. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE 6, e26906 (2011).
Itzykson, R., Kosmider, O. & Fenaux, P. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes. Best Pract. Res. Clin. Haematol. 26, 355–364 (2013).
Wlodarski, M. W. et al. Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A. Blood 118, 4490–4491 (2011).
Kern, W. et al. Mixed phenotype acute leukemia, T/myeloid, NOS (MPAL-TM) has a high DNMT3A mutation frequency and carries further genetic features of both AML and T-ALL: results of a comprehensive next-generation sequencing study analyzing 32 genes. Blood 120, 403 (2012).
Rajavelu, A., Jurkowska, R. Z., Fritz, J. & Jeltsch, A. Function and disruption of DNA methyltransferase 3a cooperative DNA binding and nucleoprotein filament formation. Nucleic Acids Res. 40, 569–580 (2012).
Acknowledgements
The authors thank C. Gillespie for critical comments on the manuscript. L.Y. is an M.D./Ph.D. McNair Scholar. This work was supported by US National Institutes of Health grants CA183252 and DK092883, the Sam Waxman Cancer Research Foundation and the Edward P. Evans Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
DATABASES
Supplementary information
Supplementary information S1 (table)
Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. (PDF 172 kb)
Supplementary information S2 (table)
Biochemical Impact of Mutations in Dnmt3a found in Cancer Patients (PDF 106 kb)
Glossary
- Imprinting
-
A genetic phenomenon in which the expression status of each allele of a gene is dictated by the parent from which the allele was inherited. DNA methylation plays a part in the crucial parent-specific regulation of gene expression.
- CpG
-
A dinucleotide pair on the same DNA strand consisting of cytosine (C) and guanine (G) nucleotides joined by a phosphodiester bond (p); CpGs are the predominant target of DNA methylation.
- Repetitive elements
-
Stretches of DNA that are found in multiple copies (often many thousands) throughout the genome. Most represent types of transposable elements, the activity of which is partly repressed by DNA methylation.
- Pericentromeric heterochromatin
-
Regions of compact genomic DNA and chromatin that are located near centromeres. Pericentromeric heterochromatin is associated with repressive chromatin marks and inactive gene transcription.
- Teratoma formation assay
-
A stringent test of pluripotency in which embryonic (or other) stem cells are transplanted into a mouse and examined for their ability to differentiate into all three germ layers.
- Variant-allele frequencies
-
(VAFs). The relative proportions of sequencing reads from variant alleles. Variants found at a VAF of 50% usually represent heterozygous mutations that are present in all cells within the sample (the founding clone). Lower VAFs suggest that the variant occurs in only a fraction of the cells (possible subclone).
- Compound heterozygous
-
The presence of two different mutant alleles at a particular gene locus, on each chromosome of a pair.
- Myelodysplastic syndrome
-
(MDS). A group of myeloid disorders characterized by clonal and ineffective haematopoiesis, dysplasia in one or more of the myeloid cell lines, cytopaenia(s) and increased risk of the development of acute myeloid leukaemia.
- Myeloproliferative neoplasms
-
(MPNs). A heterogeneous group of clonal haematopoietic stem cell disorders characterized by the abnormal proliferation of one or more of the myeloid lineages.
- Chronic myelomonocytic leukaemia
-
(CMML). A clonal haematological malignancy with features of both a myeloproliferative neoplasm and a myelodysplastic syndrome. CMML is characterized by persistent monocytosis, dysplasia of one or more myeloid lineages, and < 20% blasts in the blood and bone marrow. By definition, CMML lacks the breakpoint cluster region (BCR)–ABL1 fusion gene and platelet-derived growth factor receptor-α (PDGFRA) or PDGFRB rearrangements.
- Enhancers
-
Distal regulatory regions of the genome up to 1megabase upstream of transcription start sites defined by chromatin marks such as monomethylation of histone H3 lysine 4 (H3K4me1) and acetylation of H3K27 (H3K27ac). Enhancers are often bound by transcription factors.
- Secondary acute myeloid leukaemia
-
(sAML). A documented myelodysplastic syndrome or myeloproliferative neoplasm that transforms into AML. This subset of AML is now included in the category 'AML with myelodysplasia-related changes'.
- Spliceosome factor
-
A member of the large and complex molecular machinery known as the spliceosome, which functions to remove introns from a transcribed precursor mRNA.
- De novo acute myeloid leukaemia
-
(De novo AML). Initial diagnosis of AML, not preceded by myelodysplastic syndrome or myeloproliferative neoplasm, and not associated with prior chemotherapy or radiation therapy.
- Polycythaemia vera
-
A chronic myeloproliferative neoplasm characterized by aberrantly increased red blood cell production independent of the mechanisms that normally regulate erythropoiesis. Polycythaemia vera is molecularly characterized by activating mutations of the tyrosine kinase Janus kinase 2 (JAK2), which are present in nearly all patients with polycythaemia vera.
- Essential thrombocythaemia
-
A chronic myeloproliferative neoplasm characterized by increased platelet count in the peripheral blood and megakaryocyte proliferation with large and mature morphology in the bone marrow. Essential thrombocytosis is characterized molecularly by activating mutations of the tyrosine kinase Janus kinase 2 (JAK2), which are present in 40–50% of patients with essential thrombocytosis.
Rights and permissions
About this article
Cite this article
Yang, L., Rau, R. & Goodell, M. DNMT3A in haematological malignancies. Nat Rev Cancer 15, 152–165 (2015). https://doi.org/10.1038/nrc3895
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3895
This article is cited by
-
Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line
Medical Oncology (2024)
-
DNMT3A low-expression is correlated to poor prognosis in childhood B-ALL and confers resistance to daunorubicin on leukemic cells
BMC Cancer (2023)
-
Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes
Nature Cardiovascular Research (2023)
-
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
Communications Medicine (2023)
-
DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells
Nature Cell Biology (2023)